Alexion’s Acquisition of Synageva

Matthew Hurd, Legal counsel to Synageva
Alexion Pharmaceuticals will buy rival Synageva BioPharma in an $8.4 billion cash-and-stock deal that will bolster Alexion’s business in treatments for rare diseases.
Alexion’s takeover offer is aggressive: It will pay $115 in cash and 0.6581 Alexion shares for each share of Synageva, amounting to $230 in cash and stock.





![The Global Tax [r]Evolution](https://imgcdn.aiglobalmedia.net/acquisition-international/wp-content/uploads/2018/07/b59ea84e-0c19-4332-9436-82f948335d22.jpg?tr=fo-auto,c-maintain_ratio,w-434,h-244,q-100)













